Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
22/10/26	US$0.000400	0.00%	202
21/10/26	US$0.000400	0.00%	803
20/10/26	US$0.000400	0.00%	30,546
19/10/26	US$0.000400	0.00%	3,024
16/10/26	US$0.000400	0.00%	1,978

Delayed Quote OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Syros Pharmaceuticals, Inc.

Company calendar

Delayed OTC Markets 15:31:00 22/10/2026 BST			5-day change	1st Jan Change
0.000400 ^USD	0.00%		0.00%	+14.29%

23/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
18/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI

Market Cap	6.17M 5.5M 5.08M 4.61M 8.65M 584M 8.79M 61.17M 24.1M 306M 23.15M 22.65M 969M	P/E 2022	-0.48x	P/E 2023	-1.34x
Enterprise Value	-71.28M -63.63M -58.7M -53.33M -100M -6.75B -102M -707M -279M -3.54B -268M -262M -11.21B	EV / Sales 2022	-4.44x	EV / Sales 2023	12.6x
Free-Float	100%	Yield 2022 *	-	Yield 2023	-

23/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
18/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI
28/02/25	Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares	MT
28/02/25	Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025	CI
28/02/25	Syros Pharmaceuticals, Inc. Announces Management Changes	CI
22/12/24	Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from S&P Global BMI Index	CI
13/11/24	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/11/24	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
13/11/24	Syros Pharmaceuticals, Inc. Announces Event of Default Occurred Under the Loan and Security Agreement with Oxford Finance LLC	CI
12/11/24	Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	CI
31/10/24	Syros Pharmaceuticals, Inc., Q3 2024 Earnings Call, Oct 31, 2024

13/11/24	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/11/24	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/11/24	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
11/05/23	JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating	MT

Syros Pharmaceuticals, Inc. Share Price

Stocks

SYRS

US87184Q2066

Biotechnology & Medical Research

Valuation: Syros Pharmaceuticals, Inc.

Chart: Syros Pharmaceuticals, Inc.

Latest news: Syros Pharmaceuticals, Inc.

Analysts' recommendations: Syros Pharmaceuticals, Inc.

Press Releases: Syros Pharmaceuticals, Inc.

News in other languages: Syros Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Syros Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

28/02/25	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration	BU
18/11/24	Syros Pharmaceuticals : Management Change/Compensation Form 8 K	PU
13/11/24	Syros Pharmaceuticals : Announces Topline Data from SELECT MDS 1 Phase 3 Trial of Tamibarotene in Higher Risk Myelodysplastic Syndrome with RARA Gene Overexpression Form 8 K	PU
12/11/24	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	BU
01/11/24	Syros Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides a Business Update	AQ

24/07/23	USA-Les valeurs à suivre à Wall Street (actualisé)
05/08/21	Bourse Zurich: le SMI termine dans le vert juste sous les 12'200 points
05/08/21	Roche signe un accord de livraison avec Syros Pharmaceuticals

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.02
3 years	0		8.17
5 years	0		46.5
10 years	0		243.75

Manager	Title	Age	Since
Gerald Quirk CEO	Chief Executive Officer	58	21/11/2024
Karen Hunady IRC	Investor Relations Contact	-	30/09/2022
Matthew Foster PRN	Corporate Officer/Principal	-	28/02/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/12/24	Nancy Simonian	Sell	Chief Executive Officer	37,070	0.1382%
25/11/24	Nancy Simonian	Sell	Chief Executive Officer	134,713	0.5025%
19/11/24	Gerald Quirk	Sell	Chief Financial Officer	46,657	0.1740%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYROS PHARMACEUTICALS, INC.	0.00%	0.00%	0.00%	-99.98%	10.73K
WUXI APPTEC CO., LTD.	-4.10%	-8.35%	+38.48%	+66.99%	66.22B
ARGENX SE	-0.41%	+3.27%	+10.46%	+73.74%	55.2B
LONZA GROUP AG	+0.74%	+4.04%	+12.18%	+91.76%	52.79B
IQVIA HOLDINGS INC.	-0.41%	+1.65%	+26.47%	+49.98%	45.53B
BEONE MEDICINES AG	-1.25%	+2.33%	+22.09%	+126.87%	43.94B
REVOLUTION MEDICINES, INC.	-3.90%	-0.50%	+255.45%	+925.99%	41.64B
CELLTRION, INC.	-1.67%	+8.06%	+14.17%	+56.67%	34B
WUXI BIOLOGICS (CAYMAN) INC.	-8.38%	-9.01%	+25.65%	-1.82%	25.84B
GENMAB A/S	+1.30%	+4.94%	+38.23%	+28.03%	23.51B
Average	-1.78%	+3.09%	+44.32%	+131.82%	38.87B
Weighted average by Cap.	-1.85%	+3.43%	+47.92%	+160.29%

	2022	2023
Net sales	14.88M 13.28M 12.25M 11.13M 20.88M 1.41B 21.21M 148M 58.15M 738M 55.85M 54.66M 2.34B	9.94M 8.87M 8.18M 7.43M 13.95M 941M 14.16M 98.57M 38.83M 493M 37.3M 36.5M 1.56B
Net income	-94.65M -84.49M -77.94M -70.82M -133M -8.97B -135M -939M -370M -4.7B -355M -348M -14.88B	-165M -147M -136M -123M -231M -15.59B -235M -1.63B -643M -8.17B -618M -605M -25.87B
Net Debt	-139M -124M -114M -104M -195M -13.14B -198M -1.38B -542M -6.88B -521M -510M -21.81B	-77.45M -69.13M -63.78M -57.94M -109M -7.34B -110M -768M -303M -3.84B -291M -284M -12.18B

3 months	+300.00%
6 months	-11.11%
Current year	+14.29%